Arcadia Biosciences Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

RKDA$0.17+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share data)

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$6,518	$20,644
Short-term investments	5,124	—
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively	514	1,221
Inventories, net — current	1,958	2,321
Assets held for sale	51	87
Prepaid expenses and other current assets	807	795
Current assets of discontinued operations	—	330
Total current assets	14,972	25,398
Property and equipment, net	384	680
Right of use assets	792	1,848
Inventories, net — noncurrent	3,354	767
Intangible assets, net	39	40
Other noncurrent assets	164	165
Noncurrent assets of discontinued operations	—	24
Total assets	$19,705	$28,922
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$2,410	$2,855
Amounts due to related parties	58	48
Operating lease liability — current	852	1,010
Other current liabilities	270	270
Current liabilities of discontinued operations	—	26
Total current liabilities	3,590	4,209
Operating lease liability — noncurrent	155	1,007
Common stock warrant and option liabilities	1,257	806
Other noncurrent liabilities	2,000	2,000
Total liabilities	7,002	8,022
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,285,337 and 616,079 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	65	65
Additional paid-in capital	284,515	278,827
Accumulated other comprehensive income	101	—
Accumulated deficit	(271,840)	(257,859)
Total Arcadia Biosciences stockholders’ equity	12,841	21,033
Non-controlling interest	(138)	(133)
Total stockholders' equity	12,703	20,900
Total liabilities and stockholders’ equity	$19,705	$28,922

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.